( y advance NM283 or any clinic product c...)Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver,Health

y advance NM283 or any clinic product candidate or other component of our potential pipeline in the clinic or in the regulatory process. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to results of clinical trials, including additional data relating to the ongoing clinical trials evaluating NM283 and its other product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its other product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and filed with the Securities and Exchange Commission and other filings that the company makes with the Securities and Exchange Commission.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

    Pegasys(R) is registered trademarks of Hoffmann-La Roche, Inc.

    TaqMan(R) is a registered trademark of Roche Molecular Systems, Inc.


    1 Fried, M. et al., Peginterferon Alfa-2a Plus Ribavirin for Chronic

      Hepatitis C Virus Infect
'"/>




Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. Idenix Announces Data Presentations at the 2007 Digestive Disease
Week Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal
Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with
CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose
Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical
Trial of Arimoclomol in ALS